CO2022010204A2 - Anticuerpos contra la integrina alfa 11 beta 1 - Google Patents
Anticuerpos contra la integrina alfa 11 beta 1Info
- Publication number
- CO2022010204A2 CO2022010204A2 CONC2022/0010204A CO2022010204A CO2022010204A2 CO 2022010204 A2 CO2022010204 A2 CO 2022010204A2 CO 2022010204 A CO2022010204 A CO 2022010204A CO 2022010204 A2 CO2022010204 A2 CO 2022010204A2
- Authority
- CO
- Colombia
- Prior art keywords
- integrin
- beta
- antibodies against
- antibodies
- against alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción incluye anticuerpos que se unen específicamente a la integrina alfa 11 beta 1 (α11β1), así como métodos para producir y usar dichos anticuerpos. En algunas modalidades, un anticuerpo anti-a11 p1, o fragmento de unión a antígeno del mismo, es un anticuerpo monoclonal, o fragmento de unión a antígeno del mismo. La presente divulgación también proporciona el uso de dichos anticuerpos para tratar trastornos fibróticos y/o cánceres.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951723P | 2019-12-20 | 2019-12-20 | |
| US202062983155P | 2020-02-28 | 2020-02-28 | |
| US202063054717P | 2020-07-21 | 2020-07-21 | |
| PCT/US2020/066107 WO2021127500A1 (en) | 2019-12-20 | 2020-12-18 | Antibodies against integrin alpha 11 beta 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022010204A2 true CO2022010204A2 (es) | 2022-10-21 |
Family
ID=76478574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0010204A CO2022010204A2 (es) | 2019-12-20 | 2022-07-18 | Anticuerpos contra la integrina alfa 11 beta 1 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230050972A1 (es) |
| EP (1) | EP4076525A4 (es) |
| JP (1) | JP2023508286A (es) |
| KR (1) | KR20220123013A (es) |
| CN (1) | CN115135342A (es) |
| AU (1) | AU2020407124A1 (es) |
| BR (1) | BR112022012093A2 (es) |
| CA (1) | CA3165386A1 (es) |
| CL (1) | CL2022001673A1 (es) |
| CO (1) | CO2022010204A2 (es) |
| CR (1) | CR20220288A (es) |
| DO (1) | DOP2022000129A (es) |
| EC (1) | ECSP22056627A (es) |
| IL (1) | IL294047A (es) |
| MX (1) | MX2022007521A (es) |
| PE (1) | PE20221723A1 (es) |
| WO (1) | WO2021127500A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4263605A2 (en) * | 2020-12-18 | 2023-10-25 | Momenta Pharmaceuticals, Inc. | Antibodies against integrin alpha 11 beta 1 |
| WO2023238845A1 (ja) * | 2022-06-07 | 2023-12-14 | アステラス製薬株式会社 | 加齢疾患の治療又は予防のための抗インテグリンα１１抗体を含む医薬組成物 |
| WO2023250415A2 (en) * | 2022-06-22 | 2023-12-28 | Momenta Pharmaceuticals, Inc. | Antibodies against integrin alpha 11 beta 1 and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9902056D0 (sv) * | 1999-06-03 | 1999-06-03 | Active Biotech Ab | An integrin heterodimer and an alpha subunit thereof |
| WO2008075045A1 (en) * | 2006-12-18 | 2008-06-26 | Cartela R & D Ab | Binding agents to the integrin alpha-11 subunit, and uses thereof |
| WO2015161247A1 (en) * | 2014-04-17 | 2015-10-22 | Igenica Biotherapeutics, Inc. | Humanized anti-c16orf54 antibodies and methods of use thereof |
| EP3517549A1 (en) * | 2018-01-24 | 2019-07-31 | Bergen Teknologioverforing AS | Antibody against alpha-11 integrin and its use |
| EP3524625A1 (en) * | 2018-02-08 | 2019-08-14 | Bergen Teknologioverforing AS | Antibody against alpha-11 integrin and its use |
| JP7440718B2 (ja) * | 2018-03-01 | 2024-02-29 | 恭之 横崎 | 抗インテグリンα１１モノクローナル抗体、およびその利用 |
-
2020
- 2020-12-18 KR KR1020227024968A patent/KR20220123013A/ko active Search and Examination
- 2020-12-18 MX MX2022007521A patent/MX2022007521A/es unknown
- 2020-12-18 PE PE2022001106A patent/PE20221723A1/es unknown
- 2020-12-18 WO PCT/US2020/066107 patent/WO2021127500A1/en active Application Filing
- 2020-12-18 EP EP20903433.9A patent/EP4076525A4/en active Pending
- 2020-12-18 CN CN202080097123.5A patent/CN115135342A/zh active Pending
- 2020-12-18 US US17/757,607 patent/US20230050972A1/en active Pending
- 2020-12-18 CR CR20220288A patent/CR20220288A/es unknown
- 2020-12-18 JP JP2022537395A patent/JP2023508286A/ja active Pending
- 2020-12-18 CA CA3165386A patent/CA3165386A1/en active Pending
- 2020-12-18 BR BR112022012093A patent/BR112022012093A2/pt unknown
- 2020-12-18 AU AU2020407124A patent/AU2020407124A1/en active Pending
-
2022
- 2022-06-16 IL IL294047A patent/IL294047A/en unknown
- 2022-06-17 DO DO2022000129A patent/DOP2022000129A/es unknown
- 2022-06-17 CL CL2022001673A patent/CL2022001673A1/es unknown
- 2022-07-18 CO CONC2022/0010204A patent/CO2022010204A2/es unknown
- 2022-07-19 EC ECSENADI202256627A patent/ECSP22056627A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3165386A1 (en) | 2021-06-24 |
| KR20220123013A (ko) | 2022-09-05 |
| WO2021127500A9 (en) | 2021-07-29 |
| JP2023508286A (ja) | 2023-03-02 |
| CL2022001673A1 (es) | 2023-02-03 |
| US20230050972A1 (en) | 2023-02-16 |
| AU2020407124A1 (en) | 2022-07-21 |
| ECSP22056627A (es) | 2022-11-30 |
| DOP2022000129A (es) | 2022-10-31 |
| PE20221723A1 (es) | 2022-11-04 |
| EP4076525A4 (en) | 2024-05-01 |
| CR20220288A (es) | 2022-10-07 |
| EP4076525A1 (en) | 2022-10-26 |
| WO2021127500A1 (en) | 2021-06-24 |
| BR112022012093A2 (pt) | 2022-08-30 |
| CN115135342A (zh) | 2022-09-30 |
| MX2022007521A (es) | 2022-07-19 |
| IL294047A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022010204A2 (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
| ECSP20082648A (es) | Anticuerpos anti-sirpa y métodos de utilización de los mismos | |
| CO2019012210A2 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| CO2017005650A2 (es) | Anticuerpos anti-interleucina-33 | |
| CL2020001619A1 (es) | Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional solicitud 201903095) | |
| AR119295A1 (es) | Moléculas de unión a antígeno ligantes de cea | |
| BR112018012929A2 (pt) | anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda | |
| CO2021006869A2 (es) | Anticuerpos humanizados contra c-kit | |
| CO2020000214A2 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
| PE20231376A1 (es) | Anticuerpos contra el sars-cov-2 y metodos e seleccion y uso de los mismos | |
| CL2021000146A1 (es) | Anticuerpos humanizados contra psma | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| DOP2019000062A (es) | Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo | |
| CL2021000258A1 (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| CO2019011458A2 (es) | Anticuerpo monoclonal para pd-l1 | |
| CO2021006663A2 (es) | Anticuerpos anti-npr1 y su uso | |
| CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| CL2020001726A1 (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| EA201992316A1 (ru) | Композиции и способы для диагностики рака предстательной железы | |
| BR112022024262A2 (pt) | Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april | |
| CO2021008204A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso | |
| AR081321A1 (es) | N-cadherina: un blanco para el diagnostico y la terapia del cancer | |
| BR112021020532A2 (pt) | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 | |
| MD3365367T2 (ro) | Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora |